JP5163168B2 - 新規fki−3864物質およびその製造方法 - Google Patents
新規fki−3864物質およびその製造方法 Download PDFInfo
- Publication number
- JP5163168B2 JP5163168B2 JP2008032172A JP2008032172A JP5163168B2 JP 5163168 B2 JP5163168 B2 JP 5163168B2 JP 2008032172 A JP2008032172 A JP 2008032172A JP 2008032172 A JP2008032172 A JP 2008032172A JP 5163168 B2 JP5163168 B2 JP 5163168B2
- Authority
- JP
- Japan
- Prior art keywords
- fki
- substance
- culture
- present
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 106
- 238000000034 method Methods 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 21
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 20
- 244000005700 microbiome Species 0.000 claims description 17
- 241000606507 Talaromyces pinophilus Species 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 241000228143 Penicillium Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- ZQTBMGRBMQTZNU-GJLCVQKQSA-N dinapinone A Chemical compound C1[C@@H](C[C@H](O)C[C@H](O)CCCCC)OC(=O)C2=C(O)C3=C(O)C(C4=C(OC)C=C5C=C6C[C@H](OC(=O)C6=C(O)C5=C4O)C[C@H](O)C[C@H](O)CCCCC)=C(OC)C=C3C=C21 ZQTBMGRBMQTZNU-GJLCVQKQSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 238000000862 absorption spectrum Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- -1 triacylglycerol Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 241000371966 Penicillus <bivalve> Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-JVBZJRCZSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCC[14C](O)=O ZQPPMHVWECSIRJ-JVBZJRCZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 0 CCCCCC(*)CCC*=C(Cc(c1c2O)cc(cc3OC)c2c(O)c3-c(c(OC)cc(c2c3O)cc(C[C@](*=CC(*)CC(CCCCC)*O)O4)c3C4=O)c2O)OC1=O Chemical compound CCCCCC(*)CCC*=C(Cc(c1c2O)cc(cc3OC)c2c(O)c3-c(c(OC)cc(c2c3O)cc(C[C@](*=CC(*)CC(CCCCC)*O)O4)c3C4=O)c2O)OC1=O 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910001385 heavy metal Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LNKSLLXPNOTUHF-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;dodecyl sulfate Chemical compound [Na+].OCC(N)(CO)CO.CCCCCCCCCCCCOS([O-])(=O)=O LNKSLLXPNOTUHF-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/80—Penicillium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
本発明はまた、ペニシリウム属に属し、FKI-3864物質を生産する能力を有する微生物を培地に培養し、培養物中に FKI-3864 物質を蓄積せしめ、該培養物から FKI-3864 物質を採取することを特徴とする、新規 FKI-3864 物質の製造法に関するものである。この方法に用いる微生物としては、ペニシリウム・ピノフィラムFKI-3864 (Penicillium pinophilum FKI-3864) が好ましい。
1.形態的特徴
本菌株は、ツァペック・イーストエキス寒天培地、麦芽汁寒天培地、ポテト・キャロット寒天培地などで良好に生育し、各種寒天培地で分生子の着生は良好であった。
2.培養性状
各種寒天培地上で、25℃、7 日間培養した場合の肉眼的観察結果を表1に示す。
1)最適生育条件
本菌株の最適生育条件は pH 4〜 5、温度26.1〜35.7℃である。
本菌株の生育範囲は pH 2〜 8、温度14.4〜37.8℃である。
3)好気性、嫌気性の区別
好気性
上記FKI-3864株の形態的特徴、培養性状および生理的性状に基づき、既知菌種との比較を試みた結果、本菌株はペニシリウム・ピノフィラム (Penicillium pinophilum) に属する一菌株と同定し、ペニシリウム・ピノフィラムFKI-3864と命名した。なお本菌株はペニシリウム・ピノフィラムFKI-3864 (Penicillium pinophilum FKI-3864) として、独立行政法人産業技術総合研究所特許生物寄託センターに寄託されている (受領番号:FERM AP-21483)。
培養物に蓄積された本発明の新規物質を採取するには、微生物培養物から代謝産物を採取するのに通常使用される方法を用いることができる。例えば、有機溶媒による抽出、濃縮、乾燥、吸着、濾過、遠心分離、クロマトグラフィーなどの方法により目的物質を分離・精製する。
(1)性状:黄色粉末
(2)分子式:C46H58O14
HRFAB-MS (m/z) [M+H]+ 計算値835.3905, 実測値835.3934
(3)分子量:834
FAB-MS(m/z) で[M+H]+ 835 を観測
(4)紫外部吸収スペクトル:メタノール溶液中で測定した紫外部吸収スペクトルは図1に示すとおりであり、λmax (MeOH,ε): 222(26667) 、269(70000)、382(21667)
(5)赤外部吸収スペクトル:臭化カリウム錠剤法で測定した赤外吸収スペクトルは図2に示すとおりでありνmax 3398, 2924, 1637 cm-1 等に特徴的な吸収極大を示す。
(6)比旋光度: [α] D 26 +65.6°(c=0.1 、メタノール)
(7)溶剤に対する溶解性:メタノール、クロロホルムや酢酸エチルに可溶。水に不溶。
(8)プロトン及びカーボン核磁気共鳴スペクトル:重クロロホルム中で、バリアン社製600MHz核磁気共鳴スペクトロメータで測定した水素の化学シフト(ppm )及び炭素の化学シフト(ppm )は下記に示すとおりである。
δC : 14.0, 22.6, 24.9, 31.7, 32.8, 38.3, 42.3, 42.9, 55.9, 69.5, 73.2, 78.1, 98.1, 99.3, 108.2, 108.4, 116.2, 132.7, 140.1, 155.4, 161.5, 162.8, 171.3 ppm
以上のように、FKI-3864物質の各種理化学性状やスペクトルデータを詳細に検討した結果、FKI-3864物質は下記の式[I]で表される化学構造であることが決定された。
(1)性状:黄色粉末
(2)分子式:C46H58O14
HRFAB-MS (m/z) [M+H]+ 計算値835.3905, 実測値835.3923
(3)分子量:834
FAB-MS(m/z) で[M+H]+ 835 を観測
(4)紫外部吸収スペクトル:メタノール溶液中で測定した紫外部吸収スペクトルは図5に示すとおりであり、λmax (MeOH,ε): 222(27250) 、269(93000)、382(27250)
(5)赤外部吸収スペクトル:臭化カリウム錠剤法で測定した赤外吸収スペクトルは図6に示すとおりでありνmax 3403, 2929, 1639 cm-1 等に特徴的な吸収極大を示す。
(6)比旋光度: [α] D 26 −190.1 °(c=0.1 、メタノール)
(7)溶剤に対する溶解性:メタノール、クロロホルムや酢酸エチルに可溶。水に不溶。
(8)プロトン及びカーボン核磁気共鳴スペクトル:重クロロホルム中で、バリアン社製600MHz核磁気共鳴スペクトロメータで測定した水素の化学シフト(ppm )及び炭素の化学シフト(ppm )は下記に示すとおりである。
δC : 14.0, 22.6, 24.9, 31.7, 33.0, 38.4, 42.2, 42.9, 55.9, 69.6, 73.3, 78.2, 98.1, 99.3, 108.2, 108.4, 116.3, 132.7, 140.1, 155.4, 161.5, 162.9, 171.3 ppm
(9)円二色性スペクトル:λext (MeOH,Δε): 280 (-71), 251 (+85)
次に、本発明の FKI-3864-2 物質の理化学的性状について説明する。
(1)性状:黄色粉末
(2)分子式:C46H58O14
HRFAB-MS (m/z) [M+H]+ 計算値835.3905, 実測値835.3934
(3)分子量:834
FAB-MS(m/z) で[M+H]+ 835 を観測
(4)紫外部吸収スペクトル:メタノール溶液中で測定した紫外部吸収スペクトルは図9に示すとおりであり、λmax (MeOH,ε): 222(24750) 、269(80000)、382(22333)
(5)赤外部吸収スペクトル:臭化カリウム錠剤法で測定した赤外吸収スペクトルは図10に示すとおりでありνmax 3403, 2929, 1639 cm-1 等に特徴的な吸収極大を示す。
(6)比旋光度: [α] D 26 +246.3 °(c=0.1 、メタノール)
(7)溶剤に対する溶解性:メタノール、クロロホルムや酢酸エチルに可溶。水に不溶。
(8)プロトン及びカーボン核磁気共鳴スペクトル:重クロロホルム中で、バリアン社製600MHz核磁気共鳴スペクトロメータで測定した水素の化学シフト(ppm )及び炭素の化学シフト(ppm )は下記に示すとおりである。
δC : 14.0, 22.6, 24.9, 31.7, 32.8, 38.4, 42.1, 42.9, 56.0, 69.5, 73.4, 78.1, 98.1, 99.3, 108.2, 108.4, 116.3, 132.7, 140.1, 155.4, 161.5, 162.8, 171.3 ppm
(9)円二色性スペクトル:λext (MeOH,Δε): 278 (+48), 255 (-69)
以上のように、FKI-3864-1およびFKI-3864-2の理化学的性状およびスペクトルデータはFKI-3864物質とほぼ一致し、比旋光度のみが大きく異なる値を示したことからFKI-3864-1およびFKI-3864-2は立体異性体と予想された。さらに、円二色性スペクトルの解析によって第一コットン効果の正負が逆であるためFKI-3864-1およびFKI-3864-2は軸部分の立体異性体であることが明らかとなった。
寒天斜面培地 (グリセロール 0.1 % (関東化学) 、KH2PO4 .08 % (関東化学) 、K2HPO4 .02 % ( 関東化学) 、MgSO4 ・ H2O 0.02 % (和光純薬) 、KCl 0.02 % (関東化学) 、NaNO3 0.2 % ( 和光純薬) 、酵母エキス 0.02%(オリエンタル酵母)、寒天 1.5 %(清水食品)、pH 6.0に調整) で培養したFKI-3864株を、種培地 (グルコース 2 % (和光純薬) 、ポリペプトン 0.5 % (和光純薬) 、MgSO4 ・7H2O 0.05 % ( 和光純薬) 、酵母エキス 0.2 % (オリエンタル酵母) 、KH2PO4 0.1 % (関東化学) 、寒天 0.1% (清水食品)pH 6.0に調整) 100 mLを分注した500 mL容三角フラスコに一白金耳ずつ接種し、27°C で 3日間ロータリーシェイカー (210 rpm)で培養した後、生産培地 (サッカロース 3.0 % (和光純薬) 、可溶性デンプン 1.0 % (関東化学) 、麦芽エキス 0.3 % (三光純薬) 、KH2PO4 0.5 % ( 関東化学) 、Mg(SO4)2・8H2O 0.05 % ( 関東化学) 、 pH 6.0 に調整) 200 mLを分注した 1 L容ルーフラスコ (30本) に 1% 植菌し、27°C で 13 日間静置培養した。
本発明の FKI-3864 物質の細胞内トリアシルグリセロール生成に対する阻害作用について以下の方法で試験した。
FKI-3864物質 15 mgを少量のメタノールに溶解し、分取 HPLC(カラム : Develosil C30、4.5 φ× 250 mm 、野村科学) により精製を行った。85% アセトニトリル 0.05% H3PO4水溶液のアイソクラティックを移動相とし、0.8 mL/minの流速において、UV 270 nm の吸収をモニターした。保持時間11分および13分に溶出されるピークをそれぞれ分取して分取液を減圧下濃縮し、残渣水溶液を酢酸エチルで抽出し、黄色粉末の FKI-3864-1 を収量 5.0 mg 、FKI-3864-2を収量 7.0 mg で単離した。
試験例1と同様の方法を用いてFKI-3864-1物質およびFKI-3864-2物質の細胞内トリアシルグリセロール生成に対する阻害作用を測定した。その結果、FKI-3864-1物質のIC50は 12 μM 以上、FKI-3864-2物質のIC50は 0.54 μM と測定された。さらにFKI-3864-1物質およびFKI-3864-2物質を様々な比率で混合した場合の活性は表2に示す通りであり、1:1 の比で混合した場合が最も強い活性 (IC50 0.054μM ) を示した。
Claims (8)
- ペニシリウム属に属し、FKI-3864物質を生産する能力を有する微生物を培地に培養し、培養物中に FKI-3864 物質を蓄積せしめ、該培養物から FKI-3864 物質を採取することを特徴とする、請求項1または2記載の FKI-3864 物質の製造法。
- ペニシリウム属に属し、FKI-3864物質を生産する能力を有する微生物が、ペニシリウム・ピノフィラムFKI-3864 (Penicillium pinophilum FKI-3864) (FERM AP-21483) である請求項3記載の製造法。
- ペニシリウム属に属し、請求項1または2記載のFKI-3864物質を生産する能力を有する微生物。
- ペニシリウム・ピノフィラムFKI-3864 (Penicillium pinophilum FKI-3864) (FERM AP-21483) である請求項5記載の微生物。
- 請求項1または2記載の物質を有効成分とする、細胞内トリアシルグリセロール生成阻害剤。
- 請求項1または2記載の物質を有効成分とする、肥満の予防薬または治療薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008032172A JP5163168B2 (ja) | 2008-02-13 | 2008-02-13 | 新規fki−3864物質およびその製造方法 |
PCT/JP2009/052271 WO2009101956A1 (ja) | 2008-02-13 | 2009-02-12 | 新規 fki-3864 物質およびその製造方法 |
US12/867,435 US8378125B2 (en) | 2008-02-13 | 2009-02-12 | Substance FKI-3864 and method for preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008032172A JP5163168B2 (ja) | 2008-02-13 | 2008-02-13 | 新規fki−3864物質およびその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009190996A JP2009190996A (ja) | 2009-08-27 |
JP5163168B2 true JP5163168B2 (ja) | 2013-03-13 |
Family
ID=40956986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008032172A Active JP5163168B2 (ja) | 2008-02-13 | 2008-02-13 | 新規fki−3864物質およびその製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8378125B2 (ja) |
JP (1) | JP5163168B2 (ja) |
WO (1) | WO2009101956A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08182496A (ja) * | 1995-01-06 | 1996-07-16 | Kitasato Inst:The | Fo−2942物質およびその製造法 |
BR9814913A (pt) * | 1998-02-16 | 2001-10-23 | Kitasato Inst | Nova substância kf-1040 e processo para produção da mesma |
AU2856499A (en) * | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
-
2008
- 2008-02-13 JP JP2008032172A patent/JP5163168B2/ja active Active
-
2009
- 2009-02-12 US US12/867,435 patent/US8378125B2/en active Active
- 2009-02-12 WO PCT/JP2009/052271 patent/WO2009101956A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20110105769A1 (en) | 2011-05-05 |
WO2009101956A1 (ja) | 2009-08-20 |
JP2009190996A (ja) | 2009-08-27 |
US8378125B2 (en) | 2013-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR830002801B1 (ko) | 고(高) 콜레스테롤혈증치료제, 모나콜린 k의 제조방법 | |
JP2007291075A (ja) | 新規化合物ステレニン及びその製造方法 | |
WO2009101959A1 (ja) | 新規化合物ラクノクロモニン(lachnochromonin)類化合物 | |
KR100366258B1 (ko) | 신규 kf-1040 물질 및 그 제조법 | |
JP2022520180A (ja) | 納豆菌及びmk-7の生産方法 | |
JP5163168B2 (ja) | 新規fki−3864物質およびその製造方法 | |
JP5256758B2 (ja) | 新規fki−1746−1物質およびその製造方法 | |
JP4160149B2 (ja) | 新規fo−6979物質およびその製造法 | |
JP4836783B2 (ja) | 抗腫瘍剤、抗腫瘍剤の製造方法、抗腫瘍剤を含む医薬組成物、及び抗腫瘍剤産生菌 | |
JPWO2007097010A1 (ja) | Fki−2342物質およびその製造法 | |
JP3641013B2 (ja) | 新規な細胞接着阻害剤マクロスフェライドa及びb並びにそれらの製造法 | |
JP5478915B2 (ja) | 新規fki−4905物質およびその製造方法 | |
JPWO2004033703A1 (ja) | 新規マクロファージ泡沫化阻害物質fka−25およびその製造法 | |
JP4224404B2 (ja) | 破骨細胞分化抑制物質 | |
WO2006048947A1 (ja) | マクロファージ泡沫化阻害物質fki−1840およびその製造法 | |
JPH04243894A (ja) | 新規q−6402化合物およびその製造法 | |
EP0629184A1 (en) | TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS | |
JPWO2006095444A1 (ja) | ステンフォン(stemphone)類およびそれらの製造方法 | |
EP0525846A1 (en) | Sporomiella intermedia and processes therefrom | |
JP2002332297A (ja) | 生理活性化合物チロペプチンaおよびbとその製造方法 | |
JPH05255184A (ja) | 新規化合物イリシコリン酸aまたはb | |
JPWO2007108108A1 (ja) | 新規ステンフォン(stemphone)類の化合物及びその製造法 | |
CN108938605A (zh) | 一种苯酚类衍生物在制备拓扑异构酶i抑制剂中的应用 | |
JPH09202797A (ja) | 5α−還元酵素阻害化合物d1067331 | |
JP2006056806A (ja) | F−91495aおよびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100823 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121203 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151228 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5163168 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |